Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.

Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.

Fresenius Kabi has completed the divestment of a manufacturing plant in Halden, Norway, to Prange Group.

Fresenius Kabi has claimed an advantage in the biosimilar tocilizumab arena after its Tyenne rival to Actemra was approved by the US FDA in both intravenous and subcutaneous formulations.